Back
Sage Therapeutics Quote, Financials, Valuation and Earnings
Sponsored
SAGE
Sponsored
Invest. Do Good. Get Rewarded. Just $0.26/Share!
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
27
SAGE
Sage Therapeutics
Last Price:
5.15
Seasonality Move:
13.05%
7 Day Trial
ALL ACCESS PASS
$
7
Trade on Tuesday. Profit on Friday. Rinse & Repeat
Get the full details now.Sage Therapeutics Price Quote
$5.15
-0.02 (6.19%)
(Updated: November 23, 2024 at 5:52 AM ET)
Sage Therapeutics Key Stats
Sell
27
Sage Therapeutics (SAGE)
is a Sell
Day range:
$4.85 - $5.21
52-week range:
$4.62 - $28.26
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
2.94
P/B ratio:
0.57%
Volume:
870.9K
Avg. volume:
829.1K
1-year change:
-73.39%
Market cap:
$316.3M
Revenue:
$86.5M
EPS:
$-5.57
How Much Does Sage Therapeutics Make?
-
How Much Are Sage Therapeutics's Sales Annually?
SAGE Revenues are $86.5M -
How Much Profit Does Sage Therapeutics's Make A Year?
SAGE net income is -$541.5M
Is Sage Therapeutics Growing As A Company?
-
What Is Sage Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 3.37% -
What Is Sage Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Sage Therapeutics Stock Price Performance
-
Did Sage Therapeutics Stock Go Up Last Month?
Sage Therapeutics share price went down by -32.42% last month -
Did SAGE's Share Price Rise Over The Last Year?
SAGE share price fell by -73.39% over the past 1 year
What Is Sage Therapeutics 52-Week High & Low?
-
What Is Sage Therapeutics’s 52-Week High Share Price?
Sage Therapeutics has traded as high as $28.26 over the past 52 weeks -
What Is Sage Therapeutics’s 52-Week Low Share Price?
Sage Therapeutics has traded as low as $4.62 over the past 52 weeks
Sage Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Sage Therapeutics?
-
How Much Debt Does Sage Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Sage Therapeutics Have?
Cash and short term investments quarterly total is $569.2M -
What Is Sage Therapeutics’s Book Value Per Share?
Book value per share is 9.02
Is Sage Therapeutics Cash Flow Positive?
-
What Is SAGE Cash Flow From Operations?
Cash flow from operations (TTM) is -$320.2M -
What Is Sage Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $10.4M -
What Is Sage Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $262.2M
Sage Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
SAGE return on invested capital is -48.2% -
What Is Sage Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -43.07% -
What Is SAGE Return On Equity?
ROE is a measure of profitability and is -48.2%
Sage Therapeutics Earnings Date & Stock Price
-
What Is Sage Therapeutics's Stock Price Today?
A single share of SAGE can be purchased today for 5.17 -
What Is Sage Therapeutics’s Stock Symbol?
Sage Therapeutics trades on the nasdaq under the ticker symbol: SAGE -
When Is Sage Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Sage Therapeutics is scheduled on February 14, 2025 -
When Is SAGE's next ex-dividend date?
Sage Therapeutics's next ex-dividend date is November 23, 2024 -
How To Buy Sage Therapeutics Stock?
You can buy Sage Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Sage Therapeutics Competitors
-
Who Are Sage Therapeutics's Competitors?
Below is a list of companies who compete with Sage Therapeutics or are related in some way:
Sage Therapeutics Dividend Yield
-
What Is SAGE Dividend Yield?
Sage Therapeutics’s dividend yield currently is 0% -
What Is Sage Therapeutics’s Payout Ratio?
Sage Therapeutics’s payout ratio is 0% -
When Did Sage Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 23, 2024 -
What Is Sage Therapeutics’s Dividend Per Share?
Sage Therapeutics pays a dividend of $0.00 per share
Sage Therapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 1.32% |
Revenue: | 337.08% | 9.37% |
Analyst Recommendations
Buy Recommendations: | 0 |
---|---|
Hold Recommendations: | 17 |
Sell Recommendations: | 0 |
Price Target: | 9.47 |
Upside from Last Price: | 83.18% |